WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 96

Legislative bill overview

HB 96 proposes amendments to Utah law regarding ivermectin, a medication primarily used to treat parasitic infections in humans and animals. The bill has recently been introduced and referred to the House Health and Human Services Committee. Specific amendment language is not yet publicly detailed, making full analysis dependent on committee review.

Why is this important

Ivermectin has become a subject of significant public health debate, particularly regarding off-label uses for conditions like COVID-19, where medical evidence does not support effectiveness. Any legislative changes could affect prescribing practices, pharmacy regulations, or patient access to the medication, with implications for both public health messaging and individual medical decision-making.

Potential points of contention

  • Medical evidence standards: Whether amendments align with FDA guidance and peer-reviewed research on ivermectin's proven uses versus speculative applications
  • Prescriber autonomy vs. public health: Balancing physicians' ability to prescribe off-label against regulatory concerns about unproven treatments
  • Access and liability questions: Determining who bears responsibility if amendments expand availability without established clinical efficacy, and implications for pharmacies and healthcare providers

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.